NRx Pharmaceuticals, Inc. announced the filing of a patent application for NRX-100, its proprietary preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment, and manufacturing methods, including twenty claims.
If granted, this patent would provide exclusivity for NRX-100 into 2045, offering long-term intellectual property protection for the company's innovation. NRX-100 is specifically formulated without benzethonium chloride or other preservatives, which have been associated with cytotoxic or neurotoxic effects.
The company's demonstration of room temperature shelf stability in the absence of toxic excipients represents a novel pharmaceutical composition that has the potential to be listed in the FDA Orange Book. This patent filing builds on the company's recently initiated NDA filing for NRX-100 and its prior Fast Track Designation from the FDA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.